Verona Pharma plc (VRNA)
NASDAQ: VRNA · Real-Time Price · USD
93.82
-0.58 (-0.61%)
At close: Jun 27, 2025, 4:00 PM
93.40
-0.42 (-0.45%)
After-hours: Jun 27, 2025, 7:59 PM EDT
Verona Pharma Stock Forecast
Stock Price Forecast
According to 8 professional analysts, the 12-month price target for Verona Pharma stock ranges from a low of $57 to a high of $160. The average analyst price target of $105.38 forecasts a 12.32% increase in the stock price over the next year.
Price Target: $105.38 (+12.32%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Verona Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 5 |
| Buy | 3 | 3 | 3 | 1 | 1 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 5 | 5 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $76 → $160 | Buy | Maintains | $76 → $160 | +70.54% | Jun 23, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $107 → $138 | Buy | Maintains | $107 → $138 | +47.09% | Jun 20, 2025 |
| Roth Capital | Roth Capital | Strong Buy Reiterates $92 → $116 | Strong Buy | Reiterates | $92 → $116 | +23.64% | Jun 18, 2025 |
| Jefferies | Jefferies | Strong Buy Maintains $95 → $110 | Strong Buy | Maintains | $95 → $110 | +17.25% | Jun 11, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $90 → $100 | Buy | Maintains | $90 → $100 | +6.59% | Jun 11, 2025 |
Financial Forecast
Revenue This Year
419.32M
from 42.28M
Increased by 891.79%
Revenue Next Year
750.33M
from 419.32M
Increased by 78.94%
EPS This Year
0.05
from -2.16
EPS Next Year
1.50
from 0.05
Increased by 2,833.34%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 474.7M | 943.3M | 1.3B | ||
| Avg | 419.3M | 750.3M | 989.1M | ||
| Low | 361.7M | 560.4M | 747.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1,022.8% | 125.0% | 68.5% | ||
| Avg | 891.8% | 78.9% | 31.8% | ||
| Low | 755.5% | 33.7% | -0.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 0.17 | 3.98 | 4.76 |
| Avg | 0.05 | 1.50 | 3.07 |
| Low | -0.11 | 0.37 | 0.46 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | 7,702.9% | 217.9% |
| Avg | - | 2,833.3% | 104.9% |
| Low | - | 630.2% | -69.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.